Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Golikova describes the creation of a biomedical cell product testing system
Clinical trials of 11 new drugs are expected to be completed by the end of the year.
According to Tatyana Golikova, Deputy Prime Minister of Russia, who spoke at a meeting of Russia's Presidential Council for Science and Education, Russia will develop a test system to assess the safety of biomedical cell products (BMCP) this year.
"This year, eight cellular products that have passed preclinical trials have been chosen; they restore a patient's capacity for work and reduce the risk of disability in joint diseases, bone fractures, relieve the consequences of stroke, spinal injuries, burns, and trophic ulcers," Golikova stated.
Clinical trials are scheduled at Lomonosov Moscow State University, the Academician Petrovsky Russian Scientific Center of Surgery, the Koltzov Institute of Developmental Biology, and a number of other institutions. The same institutions will train health workers and ensure that new treatment methods are implemented in clinical settings.
Clinical trials of 11 new drugs are expected to be completed by the end of the year. According to the Deputy Prime Minister, the therapies are aimed at cancer and cardiovascular diseases.